KR102079404B1 - 메타-치환된 비페닐 말초 제한형 faah 억제제 - Google Patents

메타-치환된 비페닐 말초 제한형 faah 억제제 Download PDF

Info

Publication number
KR102079404B1
KR102079404B1 KR1020147007303A KR20147007303A KR102079404B1 KR 102079404 B1 KR102079404 B1 KR 102079404B1 KR 1020147007303 A KR1020147007303 A KR 1020147007303A KR 20147007303 A KR20147007303 A KR 20147007303A KR 102079404 B1 KR102079404 B1 KR 102079404B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
pain
faah
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147007303A
Other languages
English (en)
Korean (ko)
Other versions
KR20150100485A (ko
Inventor
다니엘레 피오멜리
산즈 귈예르모 모레노
티지아노 반디에라
마르코 모르
조르지오 타르지아
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
폰다치오네 이스티튜토 이탈리아노 디 테크놀로지아
유니베르시타 데글리 스투디 디 어비노 카를로 보
유니베르시타 데글리 스투디 디 파르마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아, 폰다치오네 이스티튜토 이탈리아노 디 테크놀로지아, 유니베르시타 데글리 스투디 디 어비노 카를로 보, 유니베르시타 데글리 스투디 디 파르마 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20150100485A publication Critical patent/KR20150100485A/ko
Application granted granted Critical
Publication of KR102079404B1 publication Critical patent/KR102079404B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
KR1020147007303A 2011-08-19 2012-08-17 메타-치환된 비페닐 말초 제한형 faah 억제제 Active KR102079404B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525636P 2011-08-19 2011-08-19
US61/525,636 2011-08-19
PCT/US2012/051478 WO2013028570A2 (en) 2011-08-19 2012-08-17 Meta-substituted biphenyl peripherally restricted faah inhibitors

Publications (2)

Publication Number Publication Date
KR20150100485A KR20150100485A (ko) 2015-09-02
KR102079404B1 true KR102079404B1 (ko) 2020-02-19

Family

ID=47747054

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147007303A Active KR102079404B1 (ko) 2011-08-19 2012-08-17 메타-치환된 비페닐 말초 제한형 faah 억제제

Country Status (12)

Country Link
US (1) US9745255B2 (enExample)
EP (1) EP2744778B1 (enExample)
JP (1) JP6092870B2 (enExample)
KR (1) KR102079404B1 (enExample)
CN (1) CN104203906B (enExample)
AU (1) AU2012299060B2 (enExample)
BR (1) BR112014003886B1 (enExample)
CA (1) CA2844812C (enExample)
DK (1) DK2744778T3 (enExample)
ES (1) ES2708723T3 (enExample)
MX (1) MX354772B (enExample)
WO (1) WO2013028570A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100485727B1 (ko) * 2004-06-24 2005-04-27 주식회사 바이오리더스 폴리감마글루탐산-비타민 복합체 및 그 용도
AU2012299060B2 (en) 2011-08-19 2017-06-01 Fondazione Istituto Italiano Di Tecnologia Meta-substituted biphenyl peripherally restricted FAAH inhibitors
WO2014023325A1 (en) * 2012-08-06 2014-02-13 Fondazione Istituto Italiano Di Tecnologia Multitarget faah and cox inhibitors and therapeutical uses thereof
WO2015157313A1 (en) 2014-04-07 2015-10-15 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
CN108348468A (zh) * 2015-08-11 2018-07-31 Eyesiu医疗股份有限公司 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒
ES2910787T3 (es) * 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
SG10201802129QA (en) 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
SG10201807034XA (en) 2017-09-05 2019-04-29 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
GB201802326D0 (en) 2018-02-13 2018-03-28 Ucl Business Plc Gene therapy
WO2019173394A1 (en) 2018-03-05 2019-09-12 Wylder Nation Foundation Compositions and methods for activating signaling through the cb1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin
US20220112225A1 (en) * 2019-01-10 2022-04-14 Travecta Therapeutics Pte. Ltd. Anandamide compounds
US20230313196A1 (en) * 2020-07-23 2023-10-05 John Mansell Compositions and methods for treating pain and anxiety disorders
CN120965462A (zh) * 2025-10-17 2025-11-18 四川奥邦古得药业有限公司 用于生产3,5-二醚戊苯的方法及其在制备3,5-二羟基戊苯中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033422A2 (en) * 2002-10-07 2004-04-22 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
WO2008063714A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325889A (en) 1978-08-04 1982-04-20 Bayer Aktiengesellschaft Process for the preparation of 1-amino-8-naphthol-3,6-disulphonic acid (H-acid)
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
EP0604289B1 (fr) 1992-12-17 1997-09-24 Valeo Systemes D'essuyage Procédé et dispositif d'alimentation d'un moteur électrique d'entrainement d'un bras d'essuie-glace de véhicule automobile
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
AU731672B2 (en) 1996-12-02 2001-04-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating bipolar disorders
GB9701453D0 (en) 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
NZ506465A (en) 1998-02-26 2003-08-29 Akzo Nobel Nv Derivatives of azetidine and pyrrolidine
US6348498B1 (en) 1998-05-29 2002-02-19 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US20030134894A1 (en) 1999-04-07 2003-07-17 Daniele Piomelli Methods of treating mental diseases, inflammation and pain
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
JP4488350B2 (ja) 2002-05-16 2010-06-23 セプラコール インク． 哺乳類アナンダミド輸送体を阻害するアミン、およびその使用方法
FR2842808B1 (fr) 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
FR2850377B1 (fr) 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
US9316633B2 (en) 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
TW200948805A (en) 2008-03-07 2009-12-01 Sigma Tau Ind Farmaceuti Enol carbamate derivatives as modulators of fatty acid amide hydrolase
PL2488486T3 (pl) 2009-10-13 2020-01-31 Ligand Pharmaceuticals Inc. Małocząsteczkowe związki mimetyczne hematopoetycznego czynnika wzrostu i ich zastosowania
CN103153946B (zh) 2010-07-28 2015-11-25 加利福尼亚大学董事会 外周限制性 faah 抑制剂
WO2012167133A2 (en) 2011-06-01 2012-12-06 The Regents Of The University Of California Inhibitors of anandamide transport and their therapeutic uses
AU2012299060B2 (en) 2011-08-19 2017-06-01 Fondazione Istituto Italiano Di Tecnologia Meta-substituted biphenyl peripherally restricted FAAH inhibitors
WO2015157313A1 (en) 2014-04-07 2015-10-15 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033422A2 (en) * 2002-10-07 2004-04-22 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
WO2008063714A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase

Also Published As

Publication number Publication date
HK1198644A1 (en) 2015-05-22
NZ622480A (en) 2016-05-27
EP2744778B1 (en) 2019-01-16
BR112014003886A8 (pt) 2018-01-23
EP2744778A4 (en) 2015-04-08
EP2744778A2 (en) 2014-06-25
AU2012299060A1 (en) 2014-04-03
CN104203906A (zh) 2014-12-10
ES2708723T3 (es) 2019-04-10
JP2014527532A (ja) 2014-10-16
AU2012299060B2 (en) 2017-06-01
KR20150100485A (ko) 2015-09-02
US20140288170A1 (en) 2014-09-25
BR112014003886A2 (pt) 2017-03-21
WO2013028570A2 (en) 2013-02-28
JP6092870B2 (ja) 2017-03-08
CA2844812C (en) 2019-10-22
MX2014001966A (es) 2015-04-08
DK2744778T3 (en) 2019-03-04
US9745255B2 (en) 2017-08-29
WO2013028570A3 (en) 2013-04-18
MX354772B (es) 2018-03-21
CA2844812A1 (en) 2013-02-28
CN104203906B (zh) 2018-03-13
BR112014003886B1 (pt) 2022-04-19

Similar Documents

Publication Publication Date Title
KR102079404B1 (ko) 메타-치환된 비페닐 말초 제한형 faah 억제제
CA2843265C (en) Peripherally restricted faah inhibitors
US10384997B2 (en) Bio-stable cannabinoid compounds and methods for enhancing their physiological concentration
US20170283837A1 (en) BIOENZYMATIC SYNTHESIS OF THC-v, CBV AND CBN AND THEIR USE AS THERAPEUTIC AGENTS
US20170298399A1 (en) Biosynthesis of cannabinoid prodrugs and their use as therapeutic agents
KR20150038363A (ko) 지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르
US20160235707A1 (en) Disubstituted beta-lactones as inhibitors of n-acylethanolamine acid amidase (naaa)
CA2658797A1 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
CN104860847B (zh) 利凡斯的明和咖啡酸、阿魏酸的二聚体,其制备方法及其药物组合物
HK1198644B (en) Meta-substituted biphenyl peripherally restricted faah inhibitors
WO2016173274A1 (zh) 芳香族法尼基类化合物及其应用
NZ622480B2 (en) Meta-substituted biphenyl peripherally restricted faah inhibitors
WO2025108835A1 (en) Dual nlrp1 and nlrp3 inhibitors for use as a medicament
US10537545B2 (en) Ceramide derivatives as anticancer agents
KR20080075922A (ko) 칼슘 채널 차단제로서의 디벤젠 유도체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140319

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170817

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190116

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20191125

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200213

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200213

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250123

Start annual number: 6

End annual number: 6